ERBB2 and breast carcinoma: Since only about 10% of ErbB2-overexpressing breast cancers that have not developed acquired therapeutic resistance also overexpress FGFR, uncovering the preventative application of FGFR inhibition would further broaden the clinical relevance and value of FGFR-targeted agents57.